All In Biotech

Drug Trial Radar · NCT07257185

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 17, 2026

Primary completion

Aug 31, 2027

Study completion Aug 31, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.

Conditions

  • Thyroid Eye Disease (TED)

Interventions

  • MHB018A injectionDrug

    MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

  • MHB018A injection PlaceboDrug

    6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proptosis Responder Rate at Week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.